Identifying clinical subgroups in IgG4-related disease patients using cluster analysis and IgG4-RD composite score

To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 22; no. 1; pp. 7 - 13
Main Authors Li, Jieqiong, Peng, Yu, Zhang, Yuelun, Zhang, Panpan, Liu, Zheng, Lu, Hui, Peng, Linyi, Zhu, Liang, Xue, Huadan, Zhao, Yan, Zeng, Xiaofeng, Fei, Yunyun, Zhang, Wen
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 10.01.2020
BioMed Central
BMC
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Allergy
Arthritis
Blood tests
Child
Cluster Analysis
Diagnosis
Diseases
Eigenvalues
Female
Health aspects
Humans
IgG4-RD CS
IgG4-related disease
Immunoglobulin G
Immunoglobulin G4-Related Disease - classification
Immunoglobulin G4-Related Disease - immunology
Immunoglobulin G4-Related Disease - pathology
Immunoglobulins
Immunologic deficiency syndromes
Laboratories
Laboratory test
Lymphocytes
Male
Medical research
Medical tests
Middle Aged
Organs involved
Patients
Phenotypes
Regression analysis
Statistical analysis
Young Adult
China
Cluster analysis
Organs involved
Laboratory test
IgG4-RD CS
IgG4-related disease
Online AccessGet full text

Cover

Abstract To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the "IgG4-RD CS" prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared. PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The "IgG4-RD CS" prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs. Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.
AbstractList To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved.BACKGROUNDTo explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved.Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the "IgG4-RD CS" prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared.METHODSTwenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the "IgG4-RD CS" prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared.PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The "IgG4-RD CS" prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs.RESULTSPCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The "IgG4-RD CS" prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs.Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.CONCLUSIONOur study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.
To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the "IgG4-RD CS" prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared. PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The "IgG4-RD CS" prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs. Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.
Background To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Methods Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the "IgG4-RD CS" prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared. Results PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The "IgG4-RD CS" prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs. Conclusion Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity. Keywords: IgG4-related disease, Laboratory test, Organs involved, Cluster analysis, IgG4-RD CS
To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the "IgG4-RD CS" prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared. PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The "IgG4-RD CS" prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs. Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.
Background To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Methods Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the “IgG4-RD CS” prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared. Results PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The “IgG4-RD CS” prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs. Conclusion Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.
Abstract Background To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Methods Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the “IgG4-RD CS” prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared. Results PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The “IgG4-RD CS” prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs. Conclusion Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.
ArticleNumber 7
Audience Academic
Author Peng, Linyi
Zhang, Panpan
Lu, Hui
Zhang, Yuelun
Fei, Yunyun
Peng, Yu
Zhu, Liang
Zeng, Xiaofeng
Li, Jieqiong
Xue, Huadan
Zhao, Yan
Zhang, Wen
Liu, Zheng
Author_xml – sequence: 1
  givenname: Jieqiong
  surname: Li
  fullname: Li, Jieqiong
– sequence: 2
  givenname: Yu
  surname: Peng
  fullname: Peng, Yu
– sequence: 3
  givenname: Yuelun
  surname: Zhang
  fullname: Zhang, Yuelun
– sequence: 4
  givenname: Panpan
  surname: Zhang
  fullname: Zhang, Panpan
– sequence: 5
  givenname: Zheng
  surname: Liu
  fullname: Liu, Zheng
– sequence: 6
  givenname: Hui
  surname: Lu
  fullname: Lu, Hui
– sequence: 7
  givenname: Linyi
  surname: Peng
  fullname: Peng, Linyi
– sequence: 8
  givenname: Liang
  surname: Zhu
  fullname: Zhu, Liang
– sequence: 9
  givenname: Huadan
  surname: Xue
  fullname: Xue, Huadan
– sequence: 10
  givenname: Yan
  surname: Zhao
  fullname: Zhao, Yan
– sequence: 11
  givenname: Xiaofeng
  surname: Zeng
  fullname: Zeng, Xiaofeng
– sequence: 12
  givenname: Yunyun
  orcidid: 0000-0003-1728-2342
  surname: Fei
  fullname: Fei, Yunyun
– sequence: 13
  givenname: Wen
  surname: Zhang
  fullname: Zhang, Wen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31924265$$D View this record in MEDLINE/PubMed
BookMark eNp1kk2L1TAYhYuMOB_6A9xIwY2bjvlqkm6EYdTxwoAgug5v07c1l7apSSvcf29qZ3TuoGSRkJzzhJOc8-xk9CNm2UtKLinV8m2knKiyILQqGKlIUT3JzqhQupBcspMH69PsPMY9IYxVTDzLTjlNM5PlWRZ2DY6zaw9u7HLbu9FZ6PO41F3wyxRzN-a77kYUAXuYsckbFxEi5hPMLhljvsTNucQZQw4j9IfoYlo0m_HL-9z6YfLRzZhH6wM-z5620Ed8cTdfZN8-fvh6_am4_Xyzu766Laxkci64Bs0phYYLpYjUUgpFtISqZa0EyViJVigGDDQjCmXd1AJazgRvheai5hfZbuM2HvZmCm6AcDAenPm94UNnIMzO9miUQIm8lkhbJTSyWpSMok18hbWSJLHebaxpqQdsbIoeoD-CHp-M7rvp_E8jq1KUagW8uQME_2PBOJvBRYt9DyP6JRrG0zelgJwl6etH0r1fQnrYVSWIVIrr8q-qgxTAja1P99oVaq4k1aqkUvGkuvyHKo0GB2dTm1qX9o8Mrx4G_ZPwvjFJoDaBDT7GgK2xbk5l8Gtu1xtKzNpNs3XTpG6atZumSk76yHkP_7_nF08N5Eg
CitedBy_id crossref_primary_10_3389_fimmu_2022_1020459
crossref_primary_10_1093_rheumatology_keab634
crossref_primary_10_1007_s12149_021_01691_8
crossref_primary_10_1111_joim_13477
crossref_primary_10_1097_CM9_0000000000002755
crossref_primary_10_1186_s12967_021_03051_6
crossref_primary_10_12677_acm_2025_153763
crossref_primary_10_1080_0886022X_2022_2064303
crossref_primary_10_12677_ACM_2023_132295
crossref_primary_10_1093_rheumatology_keaa317
crossref_primary_10_1017_S1355617722000418
crossref_primary_10_1016_j_waojou_2023_100765
crossref_primary_10_1097_APO_0000000000000552
crossref_primary_10_3389_fimmu_2021_747076
Cites_doi 10.1007/s00296-017-3730-5
10.1093/rheumatology/kex455
10.1111/odi.12526
10.1016/j.jaci.2015.12.1330
10.1016/j.ejim.2015.09.022
10.3109/03009742.2015.1055796
10.1186/s12891-015-0584-4
10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5
10.1016/j.cgh.2017.02.007
10.1002/art.39205
10.1002/art.27435
10.1093/rheumatology/kev244
10.2147/TCRM.S99985
10.1186/s13075-018-1567-2
10.1002/art.40556
10.3109/s10165-011-0571-z
10.3899/jrheum.100383
10.1080/01621459.1963.10500845
10.1016/S0140-6736(14)60720-0
10.1038/s41598-017-06520-5
10.1136/annrheumdis-2014-206605
10.1186/s13075-017-1231-2
10.1093/rheumatology/kev438
10.1007/s00405-018-5013-5
10.1177/0003489415593557
10.1093/rheumatology/key227
10.1038/s41598-017-17602-9
10.1080/14397595.2017.1416891
10.1155/2012/198314
10.1093/rheumatology/kev203
10.1186/s13075-017-1467-x
10.1136/rmdopen-2017-000432
10.3109/14397595.2015.1072296
10.1002/art.40180
10.1155/2012/572539
10.1016/j.berh.2016.07.003
10.1111/imj.13430
10.1007/s10157-011-0521-2
10.1097/BOR.0000000000000383
10.1002/art.39132
10.1093/rheumatology/key397
10.1016/j.jaci.2017.07.024
10.12659/AJCR.893300
10.1136/annrheumdis-2018-214603
10.4103/0366-6999.184459
10.1016/j.rmed.2017.09.006
10.1155/2012/259408
10.1016/j.humpath.2018.07.008
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13075-019-2090-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ - Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1478-6362
EndPage 13
ExternalDocumentID oai_doaj_org_article_74e6e3b6e1f748e2b4521ecc477eb760
PMC6954570
A618751673
31924265
10_1186_s13075_019_2090_9
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBLON
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
INH
INR
ITC
KQ8
M1P
O5R
O5S
O9-
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
IAO
IHR
NPM
Z7U
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c626t-38a8311ad34770686647086a9f2f6a6225ec472a2a8207e6bdb4af3243f4834b3
IEDL.DBID 7X7
ISSN 1478-6362
1478-6354
IngestDate Wed Aug 27 01:30:48 EDT 2025
Thu Aug 21 18:25:56 EDT 2025
Fri Jul 11 14:27:10 EDT 2025
Fri Jul 25 05:19:18 EDT 2025
Tue Jun 17 21:02:11 EDT 2025
Tue Jun 10 20:46:23 EDT 2025
Thu Jan 02 22:57:44 EST 2025
Tue Jul 01 04:00:54 EDT 2025
Thu Apr 24 23:08:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Cluster analysis
Organs involved
Laboratory test
IgG4-RD CS
IgG4-related disease
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c626t-38a8311ad34770686647086a9f2f6a6225ec472a2a8207e6bdb4af3243f4834b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1728-2342
OpenAccessLink https://www.proquest.com/docview/2340677385?pq-origsite=%requestingapplication%
PMID 31924265
PQID 2340677385
PQPubID 42876
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_74e6e3b6e1f748e2b4521ecc477eb760
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6954570
proquest_miscellaneous_2336247032
proquest_journals_2340677385
gale_infotracmisc_A618751673
gale_infotracacademiconefile_A618751673
pubmed_primary_31924265
crossref_citationtrail_10_1186_s13075_019_2090_9
crossref_primary_10_1186_s13075_019_2090_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-01-10
PublicationDateYYYYMMDD 2020-01-10
PublicationDate_xml – month: 01
  year: 2020
  text: 2020-01-10
  day: 10
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Arthritis research & therapy
PublicationTitleAlternate Arthritis Res Ther
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References F Yunyun (2090_CR8) 2017; 7
K Ohyama (2090_CR26) 2016; 26
F Yunyun (2090_CR9) 2019; 58
BW Higgs (2090_CR47) 2017; 7
ZS Wallace (2090_CR3) 2015; 67
S Kubo (2090_CR44) 2018; 57
K Takano (2090_CR46) 2015; 124
JH Stone (2090_CR6) 2001; 44
JH Ward (2090_CR25) 1963; 58
L Wang (2090_CR16) 2018; 20
MN Carruthers (2090_CR14) 2015; 74
Y Gao (2090_CR45) 2018; 275
T Saraya (2090_CR48) 2017; 132
T Sasaki (2090_CR36) 2017; 3
T Kamisawa (2090_CR1) 2015; 385
Y Sato (2090_CR37) 2012; 2012
K Kiyama (2090_CR49) 2015; 16
S Kawa (2090_CR28) 2012; 2012
N Gupta (2090_CR12) 2018; 38
D Lang (2090_CR39) 2016; 12
ZS Wallace (2090_CR27) 2019; 78
A Khosroshahi (2090_CR7) 2015; 67
L Wang (2090_CR20) 2019; 58
Y Chen (2090_CR40) 2018; 70
C Campochiaro (2090_CR23) 2016; 45
EA Rodriguez (2090_CR31) 2015; 16
GE Fragoulis (2090_CR51) 2017; 23
E Bozzalla Cassione (2090_CR32) 2017; 29
H Mattoo (2090_CR41) 2016; 138
H Umehara (2090_CR4) 2012; 22
EL Culver (2090_CR35) 2017; 15
M Kihara (2090_CR33) 2013; 31
W Lin (2090_CR42) 2017; 19
R Wang (2090_CR18) 2018; 81
S Kubo (2090_CR24) 2017; 69
MN Carruthers (2090_CR5) 2012; 2012
L Vasaitis (2090_CR38) 2016; 27
T Saeki (2090_CR34) 2018; 28
A Khosroshahi (2090_CR13) 2010; 62
GE Fragoulis (2090_CR50) 2010; 37
M Kawano (2090_CR17) 2011; 15
T Sasaki (2090_CR30) 2018; 36
JJ Heeringa (2090_CR43) 2018; 141
X Hong (2090_CR21) 2015; 18
K Yamada (2090_CR29) 2017; 19
ZS Wallace (2090_CR15) 2016; 55
Y Chen (2090_CR22) 2016; 129
E Della-Torre (2090_CR10) 2015; 54
Y Wang (2090_CR11) 2017; 47
W Lin (2090_CR19) 2015; 54
P Brito-Zerón (2090_CR2) 2016; 30
References_xml – volume: 38
  start-page: 203
  issue: 2
  year: 2018
  ident: 2090_CR12
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-017-3730-5
– volume: 57
  start-page: 514
  issue: 3
  year: 2018
  ident: 2090_CR44
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kex455
– volume: 23
  start-page: 152
  issue: 2
  year: 2017
  ident: 2090_CR51
  publication-title: Oral Dis
  doi: 10.1111/odi.12526
– volume: 138
  start-page: 825
  issue: 3
  year: 2016
  ident: 2090_CR41
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2015.12.1330
– volume: 27
  start-page: 1
  year: 2016
  ident: 2090_CR38
  publication-title: Eur J Intern Med
  doi: 10.1016/j.ejim.2015.09.022
– volume: 36
  start-page: 186
  year: 2018
  ident: 2090_CR30
  publication-title: Clin Exp Rheumatol
– volume: 45
  start-page: 135
  issue: 2
  year: 2016
  ident: 2090_CR23
  publication-title: Scand J Rheumatol
  doi: 10.3109/03009742.2015.1055796
– volume: 31
  start-page: 947
  issue: 6
  year: 2013
  ident: 2090_CR33
  publication-title: Clin Exp Rheumatol
– volume: 16
  start-page: 129
  year: 2015
  ident: 2090_CR49
  publication-title: BMC Musculoskelet Disord
  doi: 10.1186/s12891-015-0584-4
– volume: 44
  start-page: 912
  issue: 4
  year: 2001
  ident: 2090_CR6
  publication-title: Arthritis Rheum
  doi: 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5
– volume: 15
  start-page: 1444
  issue: 9
  year: 2017
  ident: 2090_CR35
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2017.02.007
– volume: 67
  start-page: 2466
  issue: 9
  year: 2015
  ident: 2090_CR3
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.39205
– volume: 62
  start-page: 1755
  issue: 6
  year: 2010
  ident: 2090_CR13
  publication-title: Arthritis Rheum
  doi: 10.1002/art.27435
– volume: 18
  start-page: 85
  issue: 2
  year: 2015
  ident: 2090_CR21
  publication-title: Chin J Dent Res
– volume: 54
  start-page: 1934
  issue: 10
  year: 2015
  ident: 2090_CR10
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kev244
– volume: 12
  start-page: 189
  year: 2016
  ident: 2090_CR39
  publication-title: Ther Clin Risk Manag
  doi: 10.2147/TCRM.S99985
– volume: 20
  start-page: 65
  issue: 1
  year: 2018
  ident: 2090_CR16
  publication-title: Arthritis Res Ther
  doi: 10.1186/s13075-018-1567-2
– volume: 70
  start-page: 1853
  issue: 11
  year: 2018
  ident: 2090_CR40
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.40556
– volume: 22
  start-page: 21
  issue: 1
  year: 2012
  ident: 2090_CR4
  publication-title: Mod Rheumatol
  doi: 10.3109/s10165-011-0571-z
– volume: 37
  start-page: 1369
  issue: 7
  year: 2010
  ident: 2090_CR50
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.100383
– volume: 58
  start-page: 236
  year: 1963
  ident: 2090_CR25
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1963.10500845
– volume: 385
  start-page: 1460
  issue: 9976
  year: 2015
  ident: 2090_CR1
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(14)60720-0
– volume: 7
  start-page: 6195
  issue: 1
  year: 2017
  ident: 2090_CR8
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-06520-5
– volume: 74
  start-page: 1171
  issue: 6
  year: 2015
  ident: 2090_CR14
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2014-206605
– volume: 19
  start-page: 25
  issue: 1
  year: 2017
  ident: 2090_CR42
  publication-title: Arthritis Res Ther.
  doi: 10.1186/s13075-017-1231-2
– volume: 55
  start-page: 1000
  issue: 6
  year: 2016
  ident: 2090_CR15
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kev438
– volume: 275
  start-page: 2013
  issue: 8
  year: 2018
  ident: 2090_CR45
  publication-title: Eur Arch Otorhinolaryngol
  doi: 10.1007/s00405-018-5013-5
– volume: 124
  start-page: 965
  issue: 12
  year: 2015
  ident: 2090_CR46
  publication-title: Ann Otol Rhinol Laryngol
  doi: 10.1177/0003489415593557
– volume: 58
  start-page: 52
  issue: 1
  year: 2019
  ident: 2090_CR9
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/key227
– volume: 7
  start-page: 17567
  issue: 1
  year: 2017
  ident: 2090_CR47
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-17602-9
– volume: 28
  start-page: 845
  issue: 5
  year: 2018
  ident: 2090_CR34
  publication-title: Mod Rheumatol
  doi: 10.1080/14397595.2017.1416891
– volume: 2012
  start-page: 198314
  year: 2012
  ident: 2090_CR28
  publication-title: Int J Rheumatol.
  doi: 10.1155/2012/198314
– volume: 54
  start-page: 1982
  issue: 11
  year: 2015
  ident: 2090_CR19
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kev203
– volume: 19
  start-page: 262
  issue: 1
  year: 2017
  ident: 2090_CR29
  publication-title: Arthritis Res Ther.
  doi: 10.1186/s13075-017-1467-x
– volume: 3
  issue: 1
  year: 2017
  ident: 2090_CR36
  publication-title: RMD Open
  doi: 10.1136/rmdopen-2017-000432
– volume: 26
  start-page: 248
  issue: 2
  year: 2016
  ident: 2090_CR26
  publication-title: Mod Rheumatol
  doi: 10.3109/14397595.2015.1072296
– volume: 69
  start-page: 2029
  issue: 10
  year: 2017
  ident: 2090_CR24
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.40180
– volume: 2012
  start-page: 572539
  year: 2012
  ident: 2090_CR37
  publication-title: Int J Rheumatol.
  doi: 10.1155/2012/572539
– volume: 30
  start-page: 261
  issue: 2
  year: 2016
  ident: 2090_CR2
  publication-title: Best Pract Res Clin Rheumatol
  doi: 10.1016/j.berh.2016.07.003
– volume: 47
  start-page: 680
  issue: 6
  year: 2017
  ident: 2090_CR11
  publication-title: Intern Med J
  doi: 10.1111/imj.13430
– volume: 15
  start-page: 615
  issue: 5
  year: 2011
  ident: 2090_CR17
  publication-title: Clin Exp Nephrol
  doi: 10.1007/s10157-011-0521-2
– volume: 29
  start-page: 223
  issue: 3
  year: 2017
  ident: 2090_CR32
  publication-title: Curr Opin Rheumatol
  doi: 10.1097/BOR.0000000000000383
– volume: 67
  start-page: 1688
  issue: 7
  year: 2015
  ident: 2090_CR7
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39132
– volume: 58
  start-page: 820
  issue: 5
  year: 2019
  ident: 2090_CR20
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/key397
– volume: 141
  start-page: 1831
  issue: 5
  year: 2018
  ident: 2090_CR43
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2017.07.024
– volume: 16
  start-page: 305
  year: 2015
  ident: 2090_CR31
  publication-title: Am J Case Rep
  doi: 10.12659/AJCR.893300
– volume: 78
  start-page: 406
  year: 2019
  ident: 2090_CR27
  publication-title: Ann Rheumatic Dis
  doi: 10.1136/annrheumdis-2018-214603
– volume: 129
  start-page: 1525
  issue: 13
  year: 2016
  ident: 2090_CR22
  publication-title: Chin Med J
  doi: 10.4103/0366-6999.184459
– volume: 132
  start-page: 62
  year: 2017
  ident: 2090_CR48
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2017.09.006
– volume: 2012
  start-page: 259408
  year: 2012
  ident: 2090_CR5
  publication-title: Int J Rheumatol
  doi: 10.1155/2012/259408
– volume: 81
  start-page: 220
  year: 2018
  ident: 2090_CR18
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2018.07.008
SSID ssj0022924
Score 2.3831203
Snippet To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Twenty-two...
Background To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved....
To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved. Twenty-two...
To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved.BACKGROUNDTo...
Abstract Background To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 7
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Allergy
Arthritis
Blood tests
Child
Cluster Analysis
Diagnosis
Diseases
Eigenvalues
Female
Health aspects
Humans
IgG4-RD CS
IgG4-related disease
Immunoglobulin G
Immunoglobulin G4-Related Disease - classification
Immunoglobulin G4-Related Disease - immunology
Immunoglobulin G4-Related Disease - pathology
Immunoglobulins
Immunologic deficiency syndromes
Laboratories
Laboratory test
Lymphocytes
Male
Medical research
Medical tests
Middle Aged
Organs involved
Patients
Phenotypes
Regression analysis
Statistical analysis
Young Adult
SummonAdditionalLinks – databaseName: DOAJ - Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1BS-UwEA7iYfGyuLvq1nWXCIIgFNskb5Ie3V1dFfQgCt5C0qYqSJ_Y9_7_zqR5j1cW1ou30mTaZmaSzDQz3zB2IBqAtnJlDr5UuZLG5cYEvJqAK5z2tYtlOq-u4fxOXd5P7ldKfVFM2AAPPDDuWKsAQXoIZauVCcIr3HDwvUrr4DVEbx33vIUzlVwtgW5FOsMsDRz3uFJrClKrUCuqIq9Gu1AE6_93SV7Zk8bxkisb0Nkm-5gsR34yfPEntha6z-zDVTob_8Jeh5zbmLfEFwmPvJ_7mLjR86eOXzz8UXnMXgkNT0czPCGr9pxC4IlyTtgJ3CW0ErxoBsKb35wC0CnKK_Ce4C-32N3Z6e2v8zxVVMhrdFxmOYrCyLJ0jUT2UXIIKI0-jata0YIDnNsBGSuccGgY6AC-8cq1aHPJln46ernN1rtpF74ybgIV7ahNoSmdHp0Wb5rWRI0w-IRJxooFh22d4Map6sWzjW6HATsIxaJQLAnFVhk7WpK8DFgb_-v8k8S27Egw2fEGKo9NymPfUp6MHZLQLU1m_LjapZwEHCLBYtkTKNGfK0HLjO2NeuIkrMfNC7WxaRHorZCK8PmkQWbsL5uJkgLbujCdUx-0IFAIUmRsZ9Cy5ZAkOccCkFqP9G805nFL9_QYIcKhQstYF7vvwaRvbEPQT4aCYh_32PrsdR6-oyU28z_ipPsLf-YuhA
  priority: 102
  providerName: Directory of Open Access Journals
Title Identifying clinical subgroups in IgG4-related disease patients using cluster analysis and IgG4-RD composite score
URI https://www.ncbi.nlm.nih.gov/pubmed/31924265
https://www.proquest.com/docview/2340677385
https://www.proquest.com/docview/2336247032
https://pubmed.ncbi.nlm.nih.gov/PMC6954570
https://doaj.org/article/74e6e3b6e1f748e2b4521ecc477eb760
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-2FsZexr7nrQsaDAYDU1tSJPlppFu7btAyygJ5E5Itt4XhdHHy_-9OVtKaQV-CiSQj-e6ku9Pd7wA-8kaptnJlrnwpcymMy40J-DRVrnDa1y6W6Tw7V6dz-XMxXSSHW5_CKrd7Ytyom2VNPvJDLiSBnQkz_XLzN6eqUXS7mkpoPIR9gi4jrtaLW4OLV0NRW4mWEh6sMt1qlkYd9rh3awpbq5BPqiKvRudShO__f5O-c0qNIyjvHEknT-FJ0iXZbCD-M3gQuufw6Czdlr-A1ZCFGzOZ2DYFkvUbH1M5enbdsR-X32Ue81lCw9JlDUtYqz2joHgauSE0BeYSfgk-NMPAi2-MQtIp7iuwngAxX8L85Pj319M81VjIazRl1jkSx4iydI2QWlO6iJIarRxXtbxVTqG0h1pq7rhDVUEH5RsvXYtamGjJDenFK9jrll14A8wEKuNRm0JTgj2aMd40rYk8YvAN0wyK7Re2dQIgpzoYf2w0RIyyA1EsEsUSUWyVwefdkJsBfeO-zkdEtl1HAs6OfyxXlzbJodUyqCC8CmWrpQncS9RfcIq4-uC1KjL4RES3JN44udqlLAVcIgFl2Zkq0cIrlRYZHIx6oljW4-Yt29i0LfT2lokz-LBrppEU6taF5Yb6oE6BRBA8g9cDl-2WJMhc5gpH6xH_jdY8bumuryJouKpQV9bF2_un9Q4ec3IoFBTneAB769UmvEeta-0nUbQmsH90fP7rYhJ9F_g757N_-iYrPg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9QwDI_GkIAXxH8KA4IEQkKq1ia5JH1AaDDGHdvtAW3SvWVJm45JqDeud0J8KT4jdpreViHtbW9VE1dJ7cR2Yv9MyBtWSVkXNk-ly0UquLap1h6eRtJmVrnShjKd00M5PhbfZqPZBvnb58JgWGW_J4aNupqXeEa-zbhAsDOuRx_Pf6VYNQpvV_sSGp1Y7Ps_v8Flaz9MdoG_bxnb-3L0eZzGqgJpCcb7MoXhaJ7ntuJCKUyQkEKBXW-LmtXSSpBvXwrFLLOgHJWXrnLC1mB38BoP3hyH794gN0HxZujsqdmFg8eKroiuAM8MFLmIt6i5ltst6AqFYXIFyGWRpcVAD4ZyAf8rhUtacRixeUkF7t0jd6PtSnc6YbtPNnzzgNyaxtv5h2TRZf2GzCnap1zSduVC6khLzxo6Of0q0pA_4ysaL4doxHZtKQbhI-UK0RuojXgp8FB1hN93KYbAY5yZpy0CcD4ix9fy9x-TzWbe-KeEao9lQ0qdKUzoB7fJ6arWQSY1fGGUkKz_w6aMgOdYd-OnCY6PlqZjigGmGGSKKRLyfk1y3qF9XNX5E7Jt3RGBusOL-eLUxHVvlPDScyd9XiuhPXMC7CUYIszeOyWzhLxDphvcTmBwpY1ZETBFBOYyOzIHjzKXiidka9ATtoFy2NyLjYnbUGsuFk1CXq-bkRJD6xo_X2EfsGGACZwl5EknZespcXTPmQRqNZC_wZyHLc3ZjwBSLguwzVX27OphvSK3x0fTA3MwOdx_Tu4wPMzIMMZyi2wuFyv_Aiy-pXsZlhklJ9e9rv8BoYNihQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identifying+clinical+subgroups+in+IgG4-related+disease+patients+using+cluster+analysis+and+IgG4-RD+composite+score&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Li%2C+Jieqiong&rft.au=Peng%2C+Yu&rft.au=Zhang%2C+Yuelun&rft.au=Zhang%2C+Panpan&rft.date=2020-01-10&rft.issn=1478-6362&rft.eissn=1478-6362&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs13075-019-2090-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13075_019_2090_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon